Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Minimally invasive and open sacroiliac joint fusion. Main billing specialties: neurosurgery and orthopedic spine.
Medicare fee-for-service SI joint fusion cases in the 27 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 20 | 1,201+17%/yr | +17%/yr | 0.51.9× | 59% | 2,330 in 2030+12%/yr |
| Florida | 18 | 1,158+12%/yr | +12%/yr | 0.51.7× | 66% | 2,840 in 2030+16%/yr |
| California | 23 | 583+5.4%/yr | +5.4%/yr | 0.20.6× | 32% | 500 in 2030−2.5%/yr |
| Oklahoma | 9 | 370+24%/yr | +24%/yr | 0.72.6× | 54% | 610 in 2030+8.7%/yr |
| Ohio | 7 | 367+22%/yr | +22%/yr | 0.31.1× | 11% | 610 in 2030+8.7%/yr |
| Arizona | 5 | 365+24%/yr | +24%/yr | 0.41.7× | 67% | 950 in 2030+17%/yr |
| Colorado | 9 | 330+20%/yr | +20%/yr | 0.62.3× | 11% | 570 in 2030+9.4%/yr |
| Georgia | 7 | 300+10%/yr | +10%/yr | 0.31.2× | 67% | 370 in 2030+3.5%/yr |
| Pennsylvania | 3 | 212+10%/yr | +10%/yr | 0.10.5× | 16% | 590 in 2030+19%/yr |
| South Carolina | 3 | 206+39%/yr | +39%/yr | 0.31.0× | 14% | 340 in 2030+8.7%/yr |
| Indiana | 3 | 192+9%/yr | +9%/yr | 0.20.9× | 27% | 430 in 2030+14%/yr |
| Washington | 4 | 187−0.2%/yr | −0.2%/yr | 0.20.8× | 100% | 80 in 2030−12%/yr |
| Minnesota | 3 | 178+21%/yr | +21%/yr | 0.31.3× | 41% | 350 in 2030+12%/yr |
| Missouri | 3 | 175−4%/yr | −4%/yr | 0.30.9× | 40% | 760 in 2030+28%/yr |
| Tennessee | 3 | 175+24%/yr | +24%/yr | 0.20.8× | 16% | 320 in 2030+11%/yr |
| New York | 0 | 175+8.8%/yr | +8.8%/yr | 0.10.3× | 0% | 450 in 2030+17%/yr |
| Illinois | 2 | 171+8.4%/yr | +8.4%/yr | 0.10.4× | 0% | 380 in 2030+14%/yr |
| Virginia | 3 | 167+8.3%/yr | +8.3%/yr | 0.10.6× | 0% | 390 in 2030+15%/yr |
| North Carolina | 3 | 167+8.3%/yr | +8.3%/yr | 0.10.6× | 13% | 340 in 2030+13%/yr |
| Maryland | 2 | 164+22%/yr | +22%/yr | 0.20.7× | 0% | 290 in 2030+10%/yr |
| New Jersey | 3 | 157+9.2%/yr | +9.2%/yr | 0.10.5× | 100% | 260 in 2030+9.1%/yr |
| Kansas | 5 | 149+26%/yr | +26%/yr | 0.31.3× | 50% | 80 in 2030−9.1%/yr |
| Wisconsin | 3 | 135+14%/yr | +14%/yr | 0.20.8× | 100% | 140 in 2030+0.1%/yr |
| Louisiana | 1 | 124+13%/yr | +13%/yr | 0.31.0× | 0% | 350 in 2030+19%/yr |
| Idaho | 2 | 102+43%/yr | +43%/yr | 0.51.7× | 0% | 170 in 2030+8.4%/yr |
| Alabama | 1 | 100+11%/yr | +11%/yr | 0.20.8× | 0% | 60 in 2030−8.8%/yr |
| Kentucky | 2 | 100−6.4%/yr | −6.4%/yr | 0.20.7× | 0% | 170 in 2030+8.9%/yr |
Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 103 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 52 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| SI-BONE | 15 |
| Surgentec | 8 |
| Orthofix | 5 |
| Life Spine | 4 |
| Tenon Medical | 4 |
| Aegis Spine | 3 |
| Camber Spine Technologies | 3 |
| Cutting Edge Spine | 3 |
| L&K Biomed | 3 |
| Medacta | 3 |
| Spinal Simplicity | 3 |
| Alevio | 2 |
Product codes: OUR (sacroiliac joint fixation). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +21 pts since 2019, to 45%.
The 10 busiest do 69% of the cases CMS names in Texas; 14 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Decompression & minimally invasive spine | 2,544 | 105,318−5.9%/yr | −5.9%/yr | 112,600 in 2030+1.1%/yr |
| Lumbar fusion | 2,352 | 95,082−1.5%/yr | −1.5%/yr | 107,700 in 2030+2.1%/yr |
| Cervical fusion & disc arthroplasty | 962 | 47,639−4%/yr | −4%/yr | 52,600 in 2030+1.7%/yr |
| Kyphoplasty & vertebroplasty | 453 | 42,837−5.7%/yr | −5.7%/yr | 44,800 in 2030+0.7%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 14 companies reported engagement with surgeons in the covered states worth $2.6M in consulting, speaking, meals and travel tied to these products, about $18K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.